SCHEMBL22904

SCHEMBL22904

FC(F)Oc1cccc(Br)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 1/20 0.46
MAOB P27338 7/20 0.46
MEP1B Q16820 1/20 0.43
KMT2A Q03164 2/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 2/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
TAS2R14 Q9NYV8 1/20 0.41
CYP1A2 P05177 1/20 0.40
GAA P10253 1/20 0.40
RECQL P46063 1/20 0.40
ALOX15 P16050 1/20 0.40
GFER P55789 1/20 0.40
ADAM17 P78536 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29539883 1.00 DRD1 (0.46) DRD1MAOBMEP1BKMT2ARAB9A
SCHEMBL16032169 0.83 MAOB (0.43) MAOBKMT2ARAB9ANPC1MAPT
SCHEMBL30693956 0.83 MAOB (0.43) MAOBKMT2AMAPTLMNACYP1A2
SCHEMBL2283508 0.82 MEP1B (0.39) DRD1MEP1BKMT2ARAB9ANPC1
SCHEMBL2821243 0.82 CES2 (0.50) MAOBKMT2ARAB9ANPC1MAPT
SCHEMBL2281706 0.81 RAB9A (0.45) MAOBKMT2ARAB9ANPC1MAPT
SCHEMBL13016953 0.79 DRD1 (0.51) DRD1KMT2ARAB9ANPC1MEN1
SCHEMBL7101430 0.79 KDM4E (0.48) MAOBKMT2AMAPTLMNACYP1A2
SCHEMBL8384042 0.78 NPC1 (0.49) MAOBKMT2ARAB9ANPC1MAPT
SCHEMBL1204347 0.78 NPC1 (0.49) MAOBKMT2ARAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100391923-C Alkylcyclohexyl multiple-fluorine biphenyl derivative and its preparation method and uses UNIV TSINGHUA (CN) 2008-06-04 CN claimed
CN-100372825-C 3,4-difluoro-2-methoxyl biphenyl derivative and its prepn process and application UNIV TSINGHUA (CN) 2008-03-05 CN claimed
CN-1847211-A 3,4-difluoro-2-methoxyl biphenyl derivative and its prepn process and application UNIV TSINGHUA (CN) 2006-10-18 CN claimed
CN-1762946-A Alkylcyclohexyl multiple-fluorine biphenyl derivative and its preparation method and uses UNIV TSINGHUA (CN) 2006-04-26 CN claimed
EP-4685143-A1 DOUBLE REGULATOR FOR MGLUR5 AND HDAC6 AND USE THEREOF Vivozon,Inc. (KR) 2026-01-28 EP disclosed
EP-4661964-A1 COMPOUNDS AS CCR6 INHIBITORS F. Hoffmann-La Roche AG (CH) 2025-12-17 EP disclosed
US-20250353859-A1 COMPOUNDS AS CCR6 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2025-11-20 US disclosed
US-12466781-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2025-11-11 US disclosed
US-12428411-B2 Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors MERCK SHARP & DOHME LLC (US) 2025-09-30 US disclosed
US-12410159-B2 Preparation of oxindole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors MERCK SHARP & DOHME LLC (US) 2025-09-09 US disclosed
US-20250092016-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES NOVARTIS AG (CH) 2025-03-20 US disclosed
US-20250059172-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL NIPPON SHINYAKU CO., LTD. (JP) 2025-02-20 US disclosed
CN-1829697-A Aryl-heteroaromatic products, compositions containing same and use thereof AVENTIS PHARMA SA (FR) 2006-09-06 CN disclosed
CN-1762946-A Alkylcyclohexyl multiple-fluorine biphenyl derivative and its preparation method and uses UNIV TSINGHUA (CN) 2006-04-26 CN disclosed
EP-1641765-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2006-04-05 EP disclosed
EP-1590329-A1 N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2005-11-02 EP disclosed
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AVENTIS PHARMA S. A. (FR) 2005-06-16 US disclosed
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AVENTIS PHARMA S.A. (FR) 2005-01-20 US disclosed
WO-2004108685-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-12-16 WO disclosed
WO-2004078732-A1 N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AHR, ARNT, MYC DRD1 2996/4885MAOB 195/4885MEP1B 2951/4885
US-20250059172-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL MC5R, CYP3A5, PTGIS DRD1 1133/4885MAOB 2133/4885MEP1B 618/4885
US-20250092016-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES ACE2, ACE, TMPRSS2 DRD1 4187/4885MAOB 372/4885MEP1B 1238/4885
US-12466781-B2 Thyromimetics TPO, TSHR, CHRM1 DRD1 833/4885MAOB 574/4885MEP1B 1720/4885
US-12410159-B2 Preparation of oxindole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors DGAT2, DGAT1, MOGAT2 DRD1 1622/4885MAOB 511/4885MEP1B 4502/4885
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AHR, NQO1, ARNT DRD1 2686/4885MAOB 409/4885MEP1B 1207/4885
US-12428411-B2 Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors DGAT2, DGAT1, MOGAT2 DRD1 1622/4885MAOB 511/4885MEP1B 4502/4885
US-20250353859-A1 COMPOUNDS AS CCR6 INHIBITORS CCR6, CCR4, CCR1 DRD1 1310/4885MAOB 4262/4885MEP1B 1367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.